Core Viewpoint - The performance briefing held by China General Nuclear Power Corporation (CGN) highlighted the progress of various projects, including the Huaxi proton medical project and the development of new products, while addressing investor concerns about the company's future growth and profitability [1] Group 1: Project Updates - The Huaxi proton medical project has completed equipment production but is not expected to finish acceptance testing within the year due to site readiness issues [1] - Proton therapy order business is facing delays as most public hospitals have not yet entered the procurement phase due to funding and construction challenges [1] - The company is actively tracking demand and communicating with potential hospitals to secure orders [1] Group 2: Product Development - The subsidiary Juner is developing a special PEEK product for applications in electronics, aerospace, and machinery, but it has not yet generated revenue [1] - The high-performance silicon photomultiplier packaging production line is expected to reach mass production conditions in the first half of 2025, with ongoing market development and initial sales orders [1] Group 3: Financial and Strategic Outlook - Revenue from the nuclear power sector accounts for less than 10% of the company's total revenue [1] - The company aims to achieve profitability in 2025 through cost reduction, product transformation, innovation enhancement, and deepening reforms [1] - There are currently no risks of delisting or other risk warnings for the company [1] Group 4: Corporate Governance and Future Plans - The company has no plans for a private placement at this time but will disclose any future plans as required [1] - Emphasis is placed on market expansion through product-centric strategies and active engagement with stakeholders [1] - The company is committed to embracing artificial intelligence to enhance productivity and drive business development [1]

中京光电生产的高性能硅光电倍增器 硅光电倍增器作为核心光电转换器件，因其高灵敏度、低噪声、低功耗等显著优势，在核医疗影像、核 测控装备、高能物理研究、生物科学等前沿领域应用广泛，潜力巨大。此前，国内硅光电倍增器市场长 期被国外企业主导，实现相关核心元器件自主可控已被明确列入国家《核技术应用产业高质量发展三年 行动方案(2024-2026)》。 近日，我国高性能硅光电倍增器(SiPM)国产化取得重大突破。记者从中广核核技术发展有限公司获悉， 由其旗下中广核京师光电科技(天津)有限公司打造的高性能硅光电倍增器封装产线成功通线，并提前达 成器件良率超90%的目标，标志着国内高性能硅光电倍增器产品实现国产化，打破国外长期垄断局面。 工作人员正在光刻间操作设备 为攻克这一技术，中广核技（000881）携手北京师范大学共同设立中京光电，以完全拥有自主知识产权 的外延电阻淬灭(EQR)硅光电倍增器、位置灵敏硅光电倍增器等技术为抓手，积极推动科技成果转化。 此次产线成功通线及高良率目标的达成，有效填补了国内高性能硅光电倍增器产品的空白，为产业链安 全稳定提供了有力保障。 中京光电总经理王晓峰表示，"半导体光敏传感器量产对环境 ...